NCT05774535

Brief Summary

The evaluation of carotid intima-media thickness (cIMT) has become a possible predictor of the future risk of cardiovascular diseases (CVD). Evidence to date shows that cIMT augmentation is correlated with the extent of atherosclerosis in the coronary arteries and with other risk factors for CVD. More recently, several studies have evaluated the association of cIMT with stroke, to determine whether this measure can also predict future cardiovascular events. Although the published evidence is scarce and fragmentary, the cIMT retains an increasingly interesting role as a marker of atherosclerotic pathology. The purpose of the study is to analyze cIMT in patients undergoing thyroidectomy to evaluate a possible correlation between the cIMT variation after the procedure and the cause of the thyroid disease, the levels of thyroid hormones, and the lipid or other markers of atherosclerosis levels. The primary endpoint will be the variation of the measure of the cIMT before and after surgery. Secondary endpoints will be:

  • major cardiovascular adverse events (death, major stroke, minor stroke, transient ischemic attack) in the short-term period (≤30 days after the procedure);
  • major cardiovascular adverse events (death, major stroke, minor stroke, transient ischemic attack) in the long-term period (\>30 days after the procedure);
  • the technical success of the procedure;
  • the rate of postoperative complications. To date, there are no data that differentiate patients based on the causes of thyroid disease. The results of the present study will allow for correlating the variation of the cIMT to the causes of thyroid disease, the levels of thyroid hormones, and the levels of lipid and other markers of atherosclerosis. Results from the present study may provide insights into possible areas of quality improvement. It may also influence the economic impact associated with carotid revascularization techniques, in terms of hospital charges and discharges to skilled nursing and rehabilitation facilities.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2022

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 5, 2022

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

February 22, 2023

Completed
23 days until next milestone

First Posted

Study publicly available on registry

March 17, 2023

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2024

Completed
Last Updated

October 2, 2025

Status Verified

September 1, 2025

Enrollment Period

2 years

First QC Date

February 22, 2023

Last Update Submit

September 29, 2025

Conditions

Keywords

carotid intima-media thicknesscardiovascular diseasethyroid diseasecarotid artery

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in Carotid Intima-Media Thickness (cIMT)

    cIMT is a measurement of the thickness of tunica intima and tunica media, the innermost two layers of the wall of an artery. The measurement is made by external ultrasound according to the recommendation of the Joint Carotid Intima-Media Thickness and Plaque Area Measurement in Ultrasound for Cardiovascular/Stroke Risk Monitoring.

    Baseline (10 days before the surgery), 30 days, 6 months and 12 months after the surgery

Secondary Outcomes (3)

  • Cumulative incidence of adverse events during periprocedural period

    Within 30 days after the surgery

  • Cumulative incidence of adverse events during postprocedural period

    Between 30 days after the surgery and 12 months after surgery

  • Change from baseline in lipid profile

    Baseline (10 days before the surgery), 30 days, 6 months and 12 months after the surgery

Study Arms (1)

Experimental

Patients who will undergo thyroidectomy

Other: Experimental

Interventions

Patients will undergo thyroidectomy according to the guidelines American Thyroid Association (ATA), Randolph. The following assessments will be performed within 10 days before the thyroidectomy procedure: * informed consent; * personal data and medical records; * registration of medical therapy and post-procedural pharmacological protocol * surgical check; * supra-aortic trunks EchocolorDoppler; * pre-procedural blood sampling. The following assessments will be performed after 30 days, 6 months and 12 months from the thyroidectomy procedure: * surgical checks; * registration of drug therapy; * recording of all adverse events that occurred during hospitalization * supra-aortic trunks EchocolorDoppler and cIMT measurement; * blood sampling.

Experimental

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All the potential eligible candidates will be recruited.

You may qualify if:

  • Patients undergoing thyroidectomy according to the American Thyroid Association (ATA), International neural monitoring study group guideline (INMSG), Italian Society of Endocrine Surgery (SIUEC);
  • subjects who have read and signed the informed consent;
  • subjects who undertake to undergo the instrumental examinations and visits necessary for the study during the follow-up;
  • \>18 years of age.

You may not qualify if:

  • occlusion or stenosis of at least one carotid artery, with plaque \> 30%;
  • exposure to ionizing radiation;
  • previous neck, carotid (endarterectomy or stenting) and/or thyroid surgery;
  • clinical conditions that preclude proper follow-up;
  • HIV, dialysis therapy and all clinical conditions with increased cIMT;
  • uncontrolled dyslipidemia;
  • pregnant and breastfeeding women;
  • terminal patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istituto Auxologico Italiano , IRCCS

Milan, 20145, Italy

Location

MeSH Terms

Conditions

Graves DiseaseHyperthyroidismEuthyroid GoiterThyroid NeoplasmsCardiovascular DiseasesThyroid Diseases

Condition Hierarchy (Ancestors)

ExophthalmosOrbital DiseasesEye DiseasesGoiterEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesEndocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck Neoplasms
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 22, 2023

First Posted

March 17, 2023

Study Start

September 5, 2022

Primary Completion

August 31, 2024

Study Completion

August 31, 2024

Last Updated

October 2, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will share

Locations